The Path Toward Drug Value Definition: Implications of Value Initiatives in Oncology - Archive

About Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted adviser to many of the world’s leading pharmaceutical, biotech and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Our advisory services, built on a solid foundation of market research and data, span three areas critical to bringing new medicines and pharmaceutical products to market – commercial development, clinical strategies and marketing effectiveness.

Kantar Health operates in more than 40 countries and employs more than 600 healthcare industry specialists and practitioners, including a high number of medical doctors, epidemiologists, PhDs, PharmDs and pharmacists, and biologists, biochemists and biophysicists. We work across the product lifecycle, from preclinical development to launch, and are experts at bringing multiple stakeholders together to advance the commercialization of pharmaceutical products. Our team acts as catalysts to successful decision making in the life sciences industry, helping our clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP.

If you would like us to act as catalysts for you, contact us at www.kantarhealth.com/contactus.

The Path Toward Drug Value Definition: Implications of Value Initiatives in Oncology - Archive

As prices for cancer therapies continue to rise, the value offered by treatments is coming under increased scrutiny. Provider professional organizations are responding by creating value frameworks and assessments. Building on its gold-standard NCCN Guidelines®, NCCN recently released NCCN Evidence Blocks™, which provides a graphical representation of efficacy, safety, evidence quality, evidence consistency and affordability measures to allow for easy and efficient comparisons of multiple therapies. ASCO’s Value Framework, released in August, accounts for safety and efficacy measurements and offers bonus points for products that have a positive impact on cancer-related symptoms and treatment-free intervals, drug acquisition costs and patient costs.

In this webinar “The Path toward Drug Value Definition: Implications of Value Initiatives in Oncology,” Kantar Health examines the awareness, knowledge and use of value assessment tools created by professional organizations from the oncologist, manufacturer and payer perspectives. This analysis is based on quantitative and qualitative research with payers, oncologists and manufacturers. The webinar explores:

Kantar Health is joined by Michael Kolodziej, M.D. and Lee S. Schwartzberg, MD, FACP to discuss these questions and the implications of professional organizations’ value-based initiatives.

Watch the Webinar

Panelists:


Meadow Green
Meadow Green
Consultant
Kantar Health
Michael Kolodziej, MD
Michael Kolodziej, MD
National Solutions, Office of the Chief Medical Officer
Aetha
Lee S. Schwartzberg, MD, FACP
Lee S. Schwartzberg, MD, FACP
Chief, Division of Hematology Oncology
The University of Tennessee Health Science Center

Moderated By:


Don Sharpe
Don Sharpe
President
OBR